Cargando…

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study

BACKGROUND: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk. It is debated whether sodium-glucose cotransporter 2 (SGLT2) inhibitors influence fracture risk in T2D. We aimed to investigate the risk of major osteoporotic fractures (MOF) with SGLT2 inhibitors compared to g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Mashhadi, Zheer Kejlberg, Viggers, Rikke, Starup-Linde, Jakob, Vestergaard, Peter, Gregersen, Søren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437938/ https://www.ncbi.nlm.nih.gov/pubmed/36060970 http://dx.doi.org/10.3389/fendo.2022.861422

Ejemplares similares

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study
por: Viggers, Rikke, et al.
Publicado: (2022)

Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
por: Viggers, Rikke, et al.
Publicado: (2021)

Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes
por: Starup-Linde, Jakob Kau, et al.
Publicado: (2021)

Associations with fracture in patients with diabetes: a nested case–control study
por: Starup-Linde, Jakob, et al.
Publicado: (2016)

Predictors of Mortality Subsequent to a Fracture in Diabetes Mellitus Patients
por: Westberg-Rasmussen, Sidse, et al.
Publicado: (2015)

The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity – A Post Hoc Analysis
por: Fuglsang-Nielsen, Rasmus, et al.
Publicado: (2022)

Editorial: Diabetes and bone - from cell to human
por: Vestergaard, Peter, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Glucose Tolerance Tests and Osteocalcin Responses in Healthy People
por: Starup-Linde, Jakob, et al.
Publicado: (2018)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
por: Muller, Dion R. P., et al.
Publicado: (2023)

Bone Density and Structure in Overweight Men With and Without Diabetes
por: Starup-Linde, Jakob, et al.
Publicado: (2022)

Diabetes, Biochemical Markers of Bone Turnover, Diabetes Control, and Bone
por: Starup-Linde, Jakob
Publicado: (2013)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 Inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells
por: Kalidas, Poonam, et al.
Publicado: (2019)

Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
por: González-González, José Gerardo, et al.
Publicado: (2021)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Better oral hygiene is associated with a reduced risk of osteoporotic fracture: a nationwide cohort study
por: Park, Jung-Hyun, et al.
Publicado: (2023)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
por: Hu, Weiting, et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
por: Malik, Mariam Elmegaard, et al.
Publicado: (2023)

Exosomes: A Friend or Foe for Osteoporotic Fracture?
por: Yang, Zhimin, et al.
Publicado: (2021)

Editorial: Assessment of osteoporotic fractures and risk prediction
por: Cheng, Xiaoguang, et al.
Publicado: (2022)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

Association between Serum Cholesterol Level and Osteoporotic Fractures
por: Wang, Yanmao, et al.
Publicado: (2018)

The “Three in One” Bone Repair Strategy for Osteoporotic Fractures
por: Chen, Xiao, et al.
Publicado: (2022)

The impact of fasting plasma glucose variability on osteoporotic fractures
por: Liu, Ri, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qpdgalm2509jbdh41mtq4lc15